Adherex Technologies, a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics, aims to increase the longevity and improve the quality of life for cancer patients. The company is developing Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, to improve the tolerability and effectiveness of 5-fluorouracil (5-FU), one of the most widely used oncology drugs in the world. For more information visit the company’s Web site at www.adherex.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: